IDEXX Laboratories (IDXX) Stock Price

IDEXX Laboratories Price

NASDAQ·CLOSED
590.00USD+3.76 (+0.64 %)
Market closed

Over the last 19 years IDEXX Laboratories grew revenue by 9.7% annually, reaching 4.30 B USD. Earnings per share have grown at 16.2% per year over the last 19 years. For IDEXX Laboratories, the net margin of 24.6% is up versus 23.2% a few years ago. The consensus 12-month price target for IDEXX Laboratories is 803.25 USD, about 36.1% above where the stock trades today. Of 22 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 12% above its 52-week low.

IDEXX Laboratories stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of IDEXX Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how IDEXX Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing IDEXX Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

IDEXX Laboratories Stock Price History
DateIDEXX Laboratories Price
8/6/2026590.00 USD
8/5/2026586.24 USD
8/4/2026596.93 USD
8/3/2026567.84 USD
7/31/2026559.07 USD
7/30/2026558.80 USD
7/29/2026568.90 USD
7/27/2026560.28 USD
7/23/2026539.36 USD
7/22/2026545.00 USD
7/21/2026552.46 USD
7/20/2026563.81 USD
7/17/2026567.44 USD
7/16/2026576.07 USD
7/15/2026557.02 USD
7/14/2026540.68 USD
7/13/2026564.41 USD
7/10/2026563.57 USD
7/9/2026558.60 USD
7/8/2026555.66 USD
7/7/2026570.25 USD
7/6/2026554.60 USD
7/2/2026557.80 USD
7/1/2026537.58 USD
6/30/2026526.44 USD
6/29/2026544.41 USD
6/26/2026551.50 USD
6/25/2026554.94 USD
6/24/2026549.16 USD
6/23/2026541.31 USD
6/22/2026549.47 USD
6/18/2026553.04 USD
6/17/2026570.72 USD
6/16/2026570.21 USD
6/15/2026567.87 USD
6/12/2026560.83 USD
6/11/2026552.51 USD
6/10/2026567.73 USD
6/9/2026578.89 USD
6/8/2026561.17 USD
6/5/2026563.59 USD
6/4/2026568.59 USD
6/3/2026556.00 USD
6/2/2026555.77 USD
6/1/2026560.73 USD
5/29/2026570.77 USD
5/28/2026564.59 USD
5/27/2026558.10 USD
5/26/2026556.68 USD
5/22/2026553.10 USD
5/21/2026549.85 USD
5/20/2026548.24 USD
5/19/2026546.49 USD
5/18/2026545.79 USD
5/15/2026528.79 USD
5/14/2026532.86 USD
5/13/2026528.68 USD
5/12/2026533.92 USD
5/11/2026532.00 USD
5/8/2026560.11 USD
5/7/2026572.20 USD
5/6/2026579.23 USD
5/5/2026562.97 USD
5/4/2026563.12 USD
5/1/2026567.46 USD
4/30/2026560.80 USD
4/29/2026553.66 USD
4/28/2026568.30 USD
4/27/2026574.95 USD
4/24/2026565.93 USD
4/22/2026578.35 USD
4/21/2026569.01 USD
4/20/2026583.06 USD
4/17/2026589.25 USD
4/16/2026569.95 USD
4/15/2026580.76 USD
4/14/2026584.05 USD
4/13/2026574.00 USD
4/10/2026563.00 USD
4/9/2026584.75 USD
4/8/2026591.84 USD
4/7/2026574.80 USD
4/6/2026577.44 USD
4/2/2026569.55 USD
4/1/2026564.66 USD
3/31/2026561.89 USD
3/30/2026557.09 USD
3/27/2026558.32 USD
3/26/2026573.29 USD
3/25/2026575.72 USD
3/24/2026570.21 USD
3/23/2026578.51 USD
3/20/2026577.26 USD
3/19/2026579.85 USD
3/18/2026579.85 USD
3/17/2026586.98 USD
3/16/2026584.69 USD
3/13/2026573.82 USD
3/12/2026571.21 USD
3/11/2026600.52 USD
3/10/2026598.85 USD
3/9/2026610.45 USD
3/6/2026608.41 USD
3/5/2026618.92 USD
3/4/2026648.70 USD
3/3/2026635.54 USD
3/2/2026636.70 USD
2/27/2026656.73 USD
2/26/2026660.71 USD
2/25/2026657.38 USD
2/24/2026649.23 USD
2/23/2026623.13 USD
2/20/2026635.66 USD
2/19/2026630.73 USD
2/18/2026634.90 USD
2/17/2026626.17 USD
2/13/2026629.35 USD
2/12/2026617.20 USD
2/11/2026648.73 USD
2/10/2026646.53 USD
2/9/2026639.79 USD
2/6/2026644.61 USD
2/5/2026643.59 USD
2/4/2026642.94 USD
2/3/2026632.56 USD
2/2/2026639.60 USD
1/30/2026670.46 USD
1/29/2026676.71 USD
1/28/2026687.74 USD
1/27/2026694.75 USD
1/26/2026697.82 USD
1/23/2026693.85 USD
1/22/2026691.05 USD
1/21/2026696.47 USD
1/20/2026686.03 USD
1/16/2026715.37 USD
1/15/2026712.12 USD
1/14/2026710.48 USD
1/13/2026714.04 USD
1/12/2026724.76 USD
1/9/2026713.35 USD
1/8/2026712.39 USD
1/7/2026714.55 USD
1/6/2026706.83 USD
1/5/2026682.23 USD
1/2/2026669.99 USD
12/31/2025676.53 USD
12/30/2025682.32 USD
12/29/2025687.89 USD
12/26/2025688.48 USD
12/24/2025688.18 USD
12/23/2025682.31 USD
12/22/2025702.12 USD
12/19/2025700.34 USD
12/18/2025697.10 USD
12/17/2025695.60 USD
12/16/2025693.18 USD
12/15/2025700.55 USD
12/12/2025704.20 USD
12/11/2025707.50 USD
12/10/2025703.00 USD
12/9/2025699.06 USD
12/8/2025706.65 USD
12/5/2025714.10 USD
12/4/2025717.47 USD
12/3/2025725.93 USD
12/2/2025732.73 USD
12/1/2025728.97 USD
11/28/2025752.88 USD
11/26/2025755.96 USD
11/25/2025766.68 USD
11/24/2025752.14 USD
11/21/2025725.91 USD
11/20/2025689.35 USD
11/19/2025697.51 USD
11/18/2025670.21 USD
11/17/2025669.00 USD
11/14/2025689.93 USD
11/13/2025701.48 USD
11/12/2025713.56 USD
11/11/2025712.47 USD
11/10/2025709.59 USD
11/7/2025708.45 USD
11/6/2025713.74 USD
11/5/2025720.21 USD
11/4/2025722.12 USD
11/3/2025729.39 USD
10/31/2025629.51 USD
10/30/2025626.46 USD
10/29/2025627.66 USD
10/28/2025634.36 USD
10/27/2025647.40 USD
10/24/2025640.85 USD
10/23/2025638.60 USD
10/22/2025633.78 USD
10/21/2025637.13 USD
10/20/2025643.41 USD
10/17/2025635.41 USD
10/16/2025637.34 USD
10/15/2025639.15 USD
10/14/2025636.91 USD
10/13/2025633.32 USD
10/10/2025616.15 USD
10/9/2025628.75 USD
10/8/2025629.91 USD
10/7/2025627.28 USD
10/6/2025627.78 USD
10/3/2025631.33 USD
10/2/2025633.84 USD
10/1/2025620.11 USD
9/30/2025638.89 USD
9/29/2025630.56 USD
9/28/2025630.56 USD
9/25/2025632.22 USD
9/24/2025618.17 USD
9/23/2025648.38 USD
9/22/2025644.10 USD
9/19/2025656.17 USD
9/18/2025655.51 USD
9/17/2025640.86 USD
9/16/2025645.65 USD
9/15/2025643.99 USD
9/12/2025641.15 USD
9/11/2025645.16 USD
9/10/2025637.95 USD
9/9/2025655.60 USD
9/8/2025652.83 USD
9/5/2025642.99 USD
9/4/2025640.44 USD
9/3/2025633.95 USD
9/2/2025639.45 USD
8/29/2025647.45 USD
8/28/2025647.03 USD
8/27/2025640.86 USD
8/26/2025641.72 USD
8/25/2025641.35 USD
8/22/2025645.56 USD
8/21/2025633.05 USD
8/20/2025639.85 USD
8/19/2025636.71 USD
8/18/2025637.86 USD
8/15/2025650.85 USD
8/14/2025653.95 USD
8/13/2025663.92 USD
8/12/2025652.27 USD
8/11/2025652.11 USD
8/8/2025658.07 USD
8/7/2025650.06 USD
Access this data via the Eulerpool API
Get Free API Key

IDEXX Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
3.66 B USD
1.10 B USD
845.04 M USD
Jan 1, 2024
3.90 B USD
1.13 B USD
887.87 M USD
Jan 1, 2025
4.30 B USD
1.36 B USD
1.06 B USD
Jan 1, 2026 (e)
4.71 B USD
1.39 B USD
1.19 B USD
Jan 1, 2027 (e)
5.12 B USD
1.51 B USD
1.34 B USD
Jan 1, 2028 (e)
5.59 B USD
1.64 B USD
1.52 B USD
Jan 1, 2029 (e)
6.13 B USD
1.80 B USD
1.74 B USD
Jan 1, 2030 (e)
6.98 B USD
2.05 B USD
2.11 B USD

IDEXX Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 12:32 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
1.601.781.972.212.412.713.223.373.663.904.304.715.125.596.136.98
7.8110.8710.9312.398.7212.4718.814.738.706.4810.429.418.759.129.7913.81
55.5954.9355.7156.0856.7358.0658.7659.5259.8161.0261.7961.7961.7961.7961.7961.79
0.890.981.101.241.371.571.892.002.192.382.662.913.163.453.794.31
0.300.350.410.490.550.690.930.901.101.131.361.391.511.641.802.05
18.6819.7220.9822.1922.9425.6528.9926.6729.9728.9531.6129.4229.4129.4129.4129.41
0.190.220.260.380.430.580.740.680.850.891.061.191.341.521.742.11
6.0815.6318.4743.3513.2636.0728.06-8.7424.454.9719.3912.0912.9713.2714.6121.42
91.7990.5989.0587.8187.2186.9086.1483.8283.9383.0680.6880.6880.6880.6880.6880.68
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales IDEXX Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue IDEXX Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare IDEXX Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares IDEXX Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against IDEXX Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

IDEXX Laboratories stock margins

The IDEXX Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IDEXX Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IDEXX Laboratories.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
58.76 %
28.99 %
23.17 %
Jan 1, 2022
59.52 %
26.69 %
20.17 %
Jan 1, 2023
59.82 %
29.97 %
23.08 %
Jan 1, 2024
61.04 %
28.95 %
22.78 %
Jan 1, 2025
61.80 %
31.60 %
24.62 %
Jan 1, 2026 (e)
61.80 %
29.41 %
25.21 %
Jan 1, 2027 (e)
61.80 %
29.41 %
26.20 %
Jan 1, 2028 (e)
61.80 %
29.41 %
27.19 %

IDEXX Laboratories Stock Revenue, EBIT, Earnings per Share

The IDEXX Laboratories earnings per share therefore indicates how much revenue IDEXX Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
37.33 USD
10.82 USD
8.65 USD
Jan 1, 2022
40.18 USD
10.72 USD
8.10 USD
Jan 1, 2023
43.62 USD
13.07 USD
10.07 USD
Jan 1, 2024
46.93 USD
13.59 USD
10.69 USD
Jan 1, 2025
53.35 USD
16.86 USD
13.13 USD
Jan 1, 2026 (e)
58.11 USD
17.17 USD
14.65 USD
Jan 1, 2027 (e)
63.20 USD
18.67 USD
16.56 USD
Jan 1, 2028 (e)
68.96 USD
20.37 USD
18.75 USD

IDEXX Laboratories business model & stock analysis

The history of IDEXX Laboratories Inc began in 1983 when a research team from the University of Maine developed technology for the automatic analysis of animal blood. The first products were soon sold and the company grew rapidly. Today, IDEXX is a leading global provider of veterinary diagnostic and IT solutions, recognized by customers in over 175 countries. IDEXX's business model is based on innovation and a comprehensive understanding of the needs of veterinarians and their patients. The company offers a wide range of products and solutions that make the diagnosis and treatment of animal diseases easier and more reliable. These include tests and devices for blood analysis, urine and stool diagnostics, as well as imaging, infection control, and cancer diagnostics. The company has several divisions that focus on different aspects of veterinary diagnostics. IDEXX Diagnostics is the largest business segment, offering veterinary lab services, diagnostic tests, and software solutions. IDEXX Water is a company specializing in the analysis of water samples and monitoring of environmental conditions. IDEXX Livestock, the newest division of IDEXX, provides veterinary solutions for agricultural and livestock operations. Key products of IDEXX include tests for parasites, infections, diabetes, and kidney function. The company has also developed some innovative products, such as SNAP tests, which provide fast and accurate results and can perform tests for various pathogens simultaneously. IDEXX is also a company committed to sustainability. The IDEXX Foundation was established in 2013 and has since donated over $32 million to local and global projects that aim to protect animals and the environment. Overall, IDEXX Laboratories Inc is a company specialized in veterinary diagnostic and IT solutions to support veterinarians in treating animals. The wide range of solutions and products, as well as the commitment to sustainability, make the company an important player in the market for veterinary diagnostics.

IDEXX Laboratories SWOT Analysis

Strengths

[ { "heading": "1.", "text": "Strong" }, { "heading": "2.", "text": "Technological" }, { "heading": "3.", "text": "Diverse" }, { "heading": "4.", "text": "Strong" }, { "heading": "5.", "text": "Global" } ]

[ { "heading": "1.", "text": "High" }, { "heading": "2.", "text": "Costly" }, { "heading": "3.", "text": "Dependence" }, { "heading": "4.", "text": "Regulatory" } ]

[ { "heading": "1.", "text": "Market" }, { "heading": "2.", "text": "Increasing" }, { "heading": "3.", "text": "Emerging" }, { "heading": "4.", "text": "Technological" } ]

[ { "heading": "1.", "text": "Economic" }, { "heading": "2.", "text": "Increasing" }, { "heading": "3.", "text": "Competitive" }, { "heading": "4.", "text": "Technological" } ]

Weaknesses

[ { "heading": "1.", "text": "High" }, { "heading": "2.", "text": "Costly" }, { "heading": "3.", "text": "Dependence" }, { "heading": "4.", "text": "Regulatory" } ]

[ { "heading": "1.", "text": "Market" }, { "heading": "2.", "text": "Increasing" }, { "heading": "3.", "text": "Emerging" }, { "heading": "4.", "text": "Technological" } ]

[ { "heading": "1.", "text": "Economic" }, { "heading": "2.", "text": "Increasing" }, { "heading": "3.", "text": "Competitive" }, { "heading": "4.", "text": "Technological" } ]

Opportunities

[ { "heading": "1.", "text": "Market" }, { "heading": "2.", "text": "Increasing" }, { "heading": "3.", "text": "Emerging" }, { "heading": "4.", "text": "Technological" } ]

[ { "heading": "1.", "text": "Economic" }, { "heading": "2.", "text": "Increasing" }, { "heading": "3.", "text": "Competitive" }, { "heading": "4.", "text": "Technological" } ]

Threats

[ { "heading": "1.", "text": "Economic" }, { "heading": "2.", "text": "Increasing" }, { "heading": "3.", "text": "Competitive" }, { "heading": "4.", "text": "Technological" } ]

IDEXX Laboratories Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

IDEXX Laboratories Employees
Details
Date
IDEXX Laboratories Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

IDEXX Laboratories Segments

IDEXX Laboratories Revenue by Segment (1/8)

  • 3 Years

  • 5 Years

  • Max

Product revenue
Service revenue
Details
Date
Product revenue
Service revenue
Jan 1, 2018
1.32 B USD
890.56 M USD
Jan 1, 2019
1.42 B USD
983.76 M USD
Jan 1, 2020
1.59 B USD
1.12 B USD
Jan 1, 2021
1.88 B USD
1.34 B USD
Jan 1, 2022
1.93 B USD
1.44 B USD
Jan 1, 2023
2.09 B USD
1.57 B USD

IDEXX Laboratories Revenue by Segment (2/8)

  • Max

CAG Diagnostics recurring revenue:
Veterinary software, services and diagnostic imaging systems:
CAG Diagnostics capital - instruments
Details
Date
CAG Diagnostics recurring revenue:
Product revenue
Service revenue
Veterinary software, services and diagnostic imaging systems:
CAG Diagnostics capital - instruments
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
2.94 B USD
0.00 USD
0.00 USD
279.33 M USD
137.60 M USD

IDEXX Laboratories Revenue by Segment (3/8)

  • 3 Years

  • Max

Reference laboratory diagnostic and consulting services
IDEXX VetLab consumables
Rapid assay products
Details
Date
Reference laboratory diagnostic and consulting services
IDEXX VetLab consumables
Rapid assay products
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
1.12 B USD
1.01 B USD
296.85 M USD
Jan 1, 2022
1.18 B USD
0.00 USD
313.67 M USD
Jan 1, 2023
1.28 B USD
0.00 USD
344.49 M USD

IDEXX Laboratories Revenue by Segment (4/8)

  • 3 Years

  • Max

CAG Diagnostics recurring revenue:
Veterinary software, services and diagnostic imaging systems
CAG Diagnostics capital - instruments
Details
Date
CAG Diagnostics recurring revenue:
Veterinary software, services and diagnostic imaging systems
CAG Diagnostics capital - instruments
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
2.53 B USD
206.26 M USD
149.14 M USD
Jan 1, 2022
2.66 B USD
251.19 M USD
147.33 M USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD

IDEXX Laboratories Revenue by Segment (5/8)

  • 3 Years

  • 5 Years

  • Max

CAG Diagnostics recurring revenue:
Veterinary software, services and diagnostic imaging systems
CAG Diagnostics capital - instruments
Details
Date
CAG Diagnostics recurring revenue:
Veterinary software, services and diagnostic imaging systems
CAG Diagnostics capital - instruments
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
2.11 B USD
162.98 M USD
108.95 M USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD

IDEXX Laboratories Revenue by Segment (6/8)

  • 3 Years

  • 5 Years

  • Max

CAG Diagnostics recurring revenue
Reference laboratory diagnostic and consulting services
IDEXX VetLab consumables
Rapid assay products
Veterinary software, services and diagnostic imaging systems
CAG Diagnostics capital - instruments
CAG Diagnostics services and accessories
Details
Date
CAG Diagnostics recurring revenue
Reference laboratory diagnostic and consulting services
IDEXX VetLab consumables
Rapid assay products
Veterinary software, services and diagnostic imaging systems
CAG Diagnostics capital - instruments
CAG Diagnostics services and accessories
Jan 1, 2018
1.65 B USD
746.79 M USD
617.24 M USD
217.54 M USD
146.63 M USD
134.26 M USD
72.96 M USD
Jan 1, 2019
1.83 B USD
0.00 USD
0.00 USD
0.00 USD
158.17 M USD
132.69 M USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

IDEXX Laboratories Revenue by Segment (7/8)

  • 3 Years

  • 5 Years

  • Max

CAG segment revenue
CAG
Water segment revenue
LPD
LPD segment revenue
Other segment revenue
Details
Date
CAG segment revenue
CAG
Water segment revenue
LPD
LPD segment revenue
Other segment revenue
Jan 1, 2018
0.00 USD
1.94 B USD
0.00 USD
130.58 M USD
0.00 USD
0.00 USD
Jan 1, 2019
2.12 B USD
0.00 USD
0.00 USD
0.00 USD
132.64 M USD
0.00 USD
Jan 1, 2020
2.39 B USD
0.00 USD
128.63 M USD
0.00 USD
145.85 M USD
46.42 M USD
Jan 1, 2021
2.89 B USD
0.00 USD
146.51 M USD
0.00 USD
135.89 M USD
43.01 M USD
Jan 1, 2022
3.06 B USD
0.00 USD
155.72 M USD
0.00 USD
122.61 M USD
30.20 M USD
Jan 1, 2023
3.35 B USD
0.00 USD
168.15 M USD
0.00 USD
121.66 M USD
18.79 M USD

IDEXX Laboratories Revenue by Segment (8/8)

  • 3 Years

  • 5 Years

  • Max

Water segment revenue
Other segment revenue
Details
Date
Water segment revenue
Other segment revenue
Jan 1, 2018
125.20 M USD
22.04 M USD
Jan 1, 2019
132.85 M USD
22.24 M USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD

IDEXX Laboratories Revenue by Region

  • 3 Years

  • 5 Years

  • Max

Americas
United States
Europe, the Middle East, and Africa
Europe, the Middle East and Africa
Asia Pacific
Asia Pacific Region
Canada
Germany
United Kingdom
Australia
France
Japan
China
Other Countries
Latin America
Italy
Switzerland
Spain
Netherlands
Details
Date
Americas
United States
Europe, the Middle East, and Africa
Europe, the Middle East and Africa
Asia Pacific
Asia Pacific Region
Canada
Germany
United Kingdom
Australia
France
Japan
China
Other Countries
Latin America
Italy
Switzerland
Spain
Netherlands
Jan 1, 2018
1.50 B USD
1.36 B USD
0.00 USD
472.07 M USD
0.00 USD
238.09 M USD
94.21 M USD
100.46 M USD
87.81 M USD
63.39 M USD
60.32 M USD
60.21 M USD
57.62 M USD
56.87 M USD
50.97 M USD
36.96 M USD
19.88 M USD
33.69 M USD
18.09 M USD
Jan 1, 2019
1.65 B USD
0.00 USD
0.00 USD
498.44 M USD
0.00 USD
256.89 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
1.85 B USD
0.00 USD
0.00 USD
562.77 M USD
0.00 USD
293.41 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
24.85 M USD
0.00 USD
0.00 USD
Jan 1, 2021
2.20 B USD
0.00 USD
0.00 USD
681.95 M USD
0.00 USD
331.38 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
31.98 M USD
0.00 USD
0.00 USD
Jan 1, 2022
2.40 B USD
0.00 USD
0.00 USD
647.03 M USD
0.00 USD
319.55 M USD
142.74 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
30.65 M USD
0.00 USD
0.00 USD
Jan 1, 2023
2.63 B USD
0.00 USD
0.00 USD
716.18 M USD
0.00 USD
319.31 M USD
150.11 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
34.83 M USD
0.00 USD
0.00 USD
Jan 1, 2024
2.77 B USD
2.53 B USD
0.00 USD
806.73 M USD
0.00 USD
321.02 M USD
152.89 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
3.01 B USD
2.75 B USD
937.25 M USD
0.00 USD
355.93 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

IDEXX Laboratories Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

IDEXX Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

IDEXX Laboratories annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

IDEXX Laboratories shares outstanding

The number of shares of IDEXX Laboratories was 80.68 M in 2025. This indicates how many shares IDEXX Laboratories is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
86.14 M Stocks
Jan 1, 2022
83.82 M Stocks
Jan 1, 2023
83.93 M Stocks
Jan 1, 2024
83.06 M Stocks
Jan 1, 2025
80.68 M Stocks
Jan 1, 2026 (e)
80.68 M Stocks
Jan 1, 2027 (e)
80.68 M Stocks
Jan 1, 2028 (e)
80.68 M Stocks

IDEXX Laboratories stock splits

In IDEXX Laboratories's history, there have been no stock splits.

Current IDEXX Laboratories forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
72.73 % (16)
Hold
27.27 % (6)
Sell
0.00 % (0)
12M Price Target
803.25
Last Price
586.24
Currency
USD
12M Return Potential
37.02 %
LTM Return
0 %

IDEXX Laboratories Analyst Rating Actions

DateFirmActionRatingReliability
7/27/2026
UBS
UBS
MaintainedNeutral51
4/28/2026
UBS
UBS
MaintainedNeutral51
3/31/2026
Stifel
Stifel
MaintainedBuy–
2/9/2026
Piper Sandler
Piper Sandler
MaintainedNeutral51
2/5/2026
Barclays
Barclays
MaintainedOverweight33
2/3/2026
UBS
UBS
MaintainedNeutral51
2/3/2026
BTIG
BTIG
MaintainedBuy–
11/4/2025
UBS
UBS
MaintainedNeutral51
11/4/2025
Morgan Stanley
Morgan Stanley
MaintainedOverweight60
11/4/2025
JP Morgan
JP Morgan
MaintainedOverweight80

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

IDEXX Laboratories Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/4/20264.03USD-1.22 BUSD-2026 Q2
5/5/20263.47USD-1.14 BUSD-2026 Q1
2/2/20262.99USD-1.09 BUSD-2025 Q4
4/30/20242.81USD-984.16 MUSD-2024 Q1
2/5/20242.14USD-902.91 MUSD-2023 Q4
7/31/20232.59USD-937.52 MUSD-2023 Q2
5/2/20232.45USD-899.38 MUSD-2023 Q1
1/31/20231.99USD-831.64 MUSD-2022 Q4
11/1/20222.08USD-843.24 MUSD-2022 Q3
8/2/20221.59USD-876.84 MUSD-2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the IDEXX Laboratories stock

86/100
99
Environment
99
Social
60
Governance
E

Environment

20
Scope 1 - Direct Emissions16,458
Scope 2 - Indirect emissions from purchased energy18,557
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions35,015
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees58
Percentage of women in management—
Percentage of Asian employees6.7
Share of Asian management—
Percentage of Hispanic/Latino employees6.2
Hispano/Latino Management share—
Percentage of Black employees9.2
Black Management Share—
Percentage of white employees75.6
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

IDEXX Laboratories shareholder structure

% Name
10.32466%
BLACKROCK, INC.
BLACKROCK, INC.
6.39618%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
4.82674%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
4.53463%
STATE STREET CORP
STATE STREET CORP
3.28417%
GEODE CAPITAL MANAGEMENT, LLC
GEODE CAPITAL MANAGEMENT, LLC
2.06248%
INVESCO LTD.
INVESCO LTD.
...

IDEXX Laboratories Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.60%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
9.40%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
9.34%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
8.82%
13-2628641
13-2628641
SEC ↗
8.08%
135521910
135521910
SEC ↗
8.08%
061523639
061523639
SEC ↗
7.80%
Massachusetts Financial Services Company ("MFS")
Massachusetts Financial Services Company ("MFS")
SEC ↗
7.51%
Vanguard Capital Management
Vanguard Capital Management
SEC ↗
7.50%
133240872
133240872
SEC ↗
6.40%
132667528
132667528
SEC ↗

IDEXX Laboratories Executives and Management Board

20 members · avg. age 60 · 30 % women

JM

Mr. Jonathan Mazelsky (64)

President, Chief Executive Officer, Director · since 2012

13.01 M USD

Management

TH

Dr. Tina Hunt (57)

Executive Vice President - Global Strategy and Commercial

3.73 M USD
ML

Mr. Michael Lane (57)

Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology

3.73 M USD
MS

Mr. Martin Smith (57)

Executive Vice President - Global Operations and R&D

3.72 M USD
SU

Ms. Sharon Underberg (63)

Executive Vice President, General Counsel, Corporate Secretary

1.88 M USD
AE

Mr. Andrew Emerson (42)

Executive Vice President, Chief Executive Officer, Treasurer

–
MJ

Mr. Michael Johnson (48)

Chief Human Resources Officer, Executive Vice President

–

Board of Directors

LK

Mr. Lawrence Kingsley (62)

Independent Chairman of the Board

499,937.00 USD
MS

Ms. M. Anne Szostak (74)

Independent Director

372,376.00 USD
DJ

Mr. Daniel Junius (72)

Independent Director

369,876.00 USD
IB

Ms. Irene Britt (62)

Independent Director

363,653.00 USD
BC

Mr. Bruce Claflin (73)

Independent Director

356,099.00 USD
SE

Dr. Stuart Essig (63)

Independent Director

354,876.00 USD

IDEXX Laboratories Supply Chain

IDEXX Laboratories Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
7 companies
#Nameβ 1YTrend
1
Thermo Fisher Scientific Inc.
Supplier
0.17
0.05
0.48
0.88
0.74
0.94
0.58
2
Euro Tech Holdings Company Limited
Customer
-0.24
0.36
0.09
0.62
0.79
0.93
—
3
Datadog, Inc.
Supplier
-0.09
-0.13
0.34
0.86
0.60
0.87
0.64
#Nameβ 1YTrend
1
Applied BioCode Corporation
Supplier
0.84
0.64
-0.27
-0.70
-0.75
—
—
2
Ortho Cli Dgnst Rg
Supplier·Customer
0.45
0.55
-0.01
0.29
—
—
—
3
Zhejiang Gongdong Medical Technology A
Supplier
0.40
0.10
-0.55
0.79
0.89
—
—
4
Luminex
Supplier
-0.49
-0.44
0.05
0.89
0.70
—
2.44

Frequently asked questions about IDEXX Laboratories

IDEXX Laboratories Inc is a global leader in veterinary diagnostics and software solutions. Their business model revolves around providing innovative products and services to veterinary practices, livestock producers, and pharmaceutical companies. IDEXX offers a wide range of diagnostic tests, instruments, and consumables that aid in the detection and prevention of diseases in animals. Their software solutions enable veterinary practices to streamline their operations, manage patient data, and enhance overall patient care. With a strong focus on research and development, IDEXX continuously strives to introduce advanced technologies and improve the quality of veterinary care worldwide.

IDEXX Laboratories Inc is primarily active in the animal health industry.

The main competitors of IDEXX Laboratories Inc in the market are Zoetis Inc, Heska Corporation, and Abaxis, Inc.

IDEXX Laboratories Inc. is a leading global company in veterinary diagnostics and software solutions. Founded in 1983, IDEXX has built a strong reputation for offering innovative products and services to support the animal healthcare industry. The company's mission is to improve the health and well-being of pets, livestock, and wildlife. IDEXX provides a wide range of diagnostic tests, instruments, and digital imaging systems that help veterinarians accurately diagnose diseases and ensure the best possible care for animals. With its headquarters in Maine, USA, IDEXX has an extensive network of customers worldwide. As a pioneer in animal diagnostics, IDEXX continues to drive advancements in veterinary medicine and enhance animal healthcare globally.

IDEXX Laboratories Inc, a renowned leader in veterinary diagnostics and software, has achieved numerous significant milestones over the years. The company pioneered the first veterinary reference laboratory, revolutionizing the field of animal health diagnostics. IDEXX also developed innovative technologies such as the SNAP test, providing immediate results for veterinarians. Furthermore, the company introduced groundbreaking products like the IDEXX ProCyte Dx Hematology Analyzer, enhancing the accuracy and efficiency of pet healthcare. With a commitment to continuous innovation, IDEXX Laboratories Inc has consistently redefined the standards in veterinary medicine, offering exceptional diagnostic solutions for veterinarians globally.

IDEXX Laboratories Inc is primarily present in various countries and regions worldwide. As a leading veterinary diagnostics and software provider, IDEXX operates in over 175 countries. Its operations span across North America, including the United States and Canada, as well as Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global presence, IDEXX consistently delivers innovative solutions and services to veterinary practices, animal healthcare professionals, and laboratories around the globe.

IDEXX Laboratories Inc represents strong values and a clear corporate philosophy. The company's values are centered around innovation, integrity, and collaboration. IDEXX is committed to continuously developing innovative diagnostic solutions to improve the health and well-being of animals worldwide. They uphold the highest standards of integrity in their business practices, ensuring transparency and trust with their customers and partners. Additionally, IDEXX promotes a culture of collaboration, fostering a diverse and inclusive environment that encourages teamwork and supports the growth and success of its employees. Through these values and corporate philosophy, IDEXX Laboratories Inc exemplifies its dedication to advancing animal healthcare globally.

Analysts currently set an average price target of 781.34 USD for the IDEXX Laboratories stock (median: 803.25 USD), implying +33.3 % versus the latest price. The consensus is based on 22 analyst ratings.

IDEXX Laboratories Analyst Price Targets 2026

22 analysts currently rate the IDEXX Laboratories stock: 16 recommend buying, 6 holding and 0 selling. For 2026, analysts expect IDEXX Laboratories to generate revenue of 4.71 B USD and earnings per share of 14.71 USD.

IDEXX Laboratories Analyst Price Targets 2026

Converted at the current exchange rate, the IDEXX Laboratories share trades at 510.75 EUR (590.00 USD).

The IDEXX Laboratories share (IDXX) is listed on 9 stock exchanges, including: NASDAQ (IDXX), XETRA (IX1.DE), Frankfurt (IX1.F), München (IX1.MU), Düsseldorf (IX1.DU), London (0J8P.L), London (0J8P.L), SIX (Zürich) (IX1.SW).

IDEXX Laboratories Inc is a leading company in the field of animal health diagnostics and biotechnology. The company's business model is to offer innovative solutions to veterinarians, pet owners, and animal caretakers to improve the health and well-being of animals. IDEXX is divided into three main divisions: diagnostics and software, water testing, and animal genetics. Each division offers specialized products and services to meet the individual needs and requirements of customers. The diagnostics and software division of IDEXX offers a wide range of tests and instruments for the diagnosis of diseases in animals. The products range from simple blood tests to complex pathological examinations. IDEXX Labs specializes in tests for dogs, cats, and horses, offering a wide range of diagnostic options for these animals. The company also works closely with veterinarians and veterinary clinics to provide a wide range of diagnostic and laboratory services. In the water testing division, the company develops solutions for the detection of contaminants in drinking water and bottled water. This area of the business is focused on companies and government agencies that monitor the condition of water and want to ensure that it is safe for consumption. The animal genetics division of IDEXX offers breeding programs and tests for animals. The foundation of this division's work is DNA sequencing, which allows for the identification of genetic factors that can impact the health and behavior of animals. The animal genetics department works with veterinarians and pet owners to provide customer-oriented services that contribute to the improvement of animal health and breed. IDEXX is committed to providing its customers with innovative and advanced solutions. The company continuously invests in research and development to bring new products to the market and improve its existing offerings. IDEXX's business model is based on creating value by helping veterinarians and animal caretakers improve the health, well-being, and quality of life of animals. IDEXX also aims to integrate its products and services into the online market. To achieve this, the company develops various software solutions to ensure better portability and convenient connections to its services for customers. IDEXX is already involved in telemedicine, offering pet owners the opportunity to speak with veterinarians online and receive diagnoses. Overall, IDEXX's business model is focused on providing a comprehensive platform for animal health and biotechnology. Through its divisions in diagnostics, water testing, and animal genetics, the company has developed a wide range of products and solutions aimed at improving the health and well-being of animals and providing customers with high value.

The expected revenue of IDEXX Laboratories is 4.71 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of IDEXX Laboratories is 1.19 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IDEXX Laboratories is currently 40.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IDEXX Laboratories stock.

The price-to-sales ratio (P/S) of IDEXX Laboratories is currently 10.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IDEXX Laboratories stock.

The Eulerpool Quality Score for IDEXX Laboratories is 8/10.

The ISIN of IDEXX Laboratories is US45168D1046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of IDEXX Laboratories is 888210. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of IDEXX Laboratories is IDXX. The ticker symbol is used to trade IDEXX Laboratories shares on the stock exchange.

IDEXX Laboratories paid dividends every year for the past 0 years.

IDEXX Laboratories is assigned to the 'Health' sector.

The dividends of IDEXX Laboratories are distributed in USD.

All fundamentals and in-depth analysis of IDEXX Laboratories

Our stock analysis for IDEXX Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IDEXX Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

IDEXX Laboratories Stock
IDEXX Laboratories Revenue→
IDEXX Laboratories Stock
IDEXX Laboratories Net Income→
IDEXX Laboratories Stock
IDEXX Laboratories P/E→
IDEXX Laboratories Stock
IDEXX Laboratories P/S→
IDEXX Laboratories Stock
IDEXX Laboratories EBIT→
IDEXX Laboratories Stock
IDEXX Laboratories Dividend→
IDEXX Laboratories Stock
IDEXX Laboratories Directors Dealings→
IDEXX Laboratories Stock
IDEXX Laboratories Stocks→
IDEXX Laboratories Stock
IDEXX Laboratories Market capitalization→
IDEXX Laboratories Stock
IDEXX Laboratories Debt→
IDEXX Laboratories Stock
IDEXX Laboratories Liabilities→
IDEXX Laboratories Stock
IDEXX Laboratories Equity→
IDEXX Laboratories Stock
IDEXX Laboratories AAQS→
IDEXX Laboratories Stock
IDEXX Laboratories Employees→
IDEXX Laboratories Stock
IDEXX Laboratories ROE→
IDEXX Laboratories Stock
IDEXX Laboratories ROA→
IDEXX Laboratories Stock
IDEXX Laboratories ROCE→
IDEXX Laboratories Stock
IDEXX Laboratories News→
IDEXX Laboratories Stock
IDEXX Laboratories Analyst Price Targets→

Health Stocks

IDL Diagnostics AB (publ)IDEAYA BiosciencesIdorsiaICU MedicalIDT AustraliaIconovoIfa SystemsIconic LabsIkonisysICONIl Dong Pharmaceutical CoIcecure MedicalAll Stocks A–Z →